January 7, 2026

Putting Patients First: See How NeoGenomics Supports Personalized Cancer Care

As we reflect on the past year and look ahead, one thing remains clear: patient care is at the center of everything we do. Clinical laboratories play a vital role in community oncology—delivering timely, accurate insights that guide informed, personalized cancer care at every stage of the patient journey.

We’re proud of the impact our teams have made and of our President and COO, Warren Stone, for sharing how NeoGenomics helps ensure patients receive high-quality care close to home through ACLA’s Power Of Knowing campaign.

Watch Warren discuss the important role NeoGenomics plays in supporting community oncologists and advancing personalized cancer care:

 

 

As we begin the new year, our focus remains where it matters most: patients. Together, we’ll continue bringing high-quality diagnostics closer to home.

 

c-MET CDx for NSCLC

The c-MET CDx for NSCLC IHC assay is now offered within our full NSCLC testing portfolio and can be added to any PanTracer™ Tissue order, supporting comprehensive biomarker profiling for lung cancer patients.

Discover how HGFR (MET) testing can elevate your lung cancer care approach by visiting us online.

 

For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.